Considering PYCR1, PYCR2, and HF effects on the mTOR pathway, these findings suggest targeting proline metabolism, especially via HF-mediated inhibition, as a potential therapeutic approach for renal cancer. The gene discussed is PYCR2; the disease is renal carcinoma.